Gordian Capital Singapore Pte Ltd Has $1.04 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Gordian Capital Singapore Pte Ltd lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 211.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,193 shares of the medical research company's stock after buying an additional 5,563 shares during the period. Gordian Capital Singapore Pte Ltd's holdings in Natera were worth $1,040,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in NTRA. Itau Unibanco Holding S.A. acquired a new position in Natera in the second quarter worth about $28,000. Quarry LP increased its position in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC raised its stake in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. Covestor Ltd boosted its position in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the period. Finally, True Wealth Design LLC bought a new position in shares of Natera in the third quarter worth $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company's stock, valued at $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction on Friday, September 13th. The stock was sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the transaction, the director now owns 7,969 shares in the company, valued at $1,017,481.92. This trade represents a 24.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 133,976 shares of company stock valued at $21,119,238 in the last quarter. Company insiders own 7.60% of the company's stock.

Natera Stock Performance

Natera stock traded down $3.85 during mid-day trading on Monday, hitting $167.80. The company's stock had a trading volume of 1,047,160 shares, compared to its average volume of 1,335,050. Natera, Inc. has a 52-week low of $55.56 and a 52-week high of $175.63. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm's 50 day moving average is $140.16 and its 200 day moving average is $122.63.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the firm earned ($0.95) earnings per share. The firm's revenue was up 63.9% compared to the same quarter last year. Analysts anticipate that Natera, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

NTRA has been the subject of several recent analyst reports. Sanford C. Bernstein increased their price objective on shares of Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Leerink Partners lifted their price target on Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Robert W. Baird raised their target price on Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Morgan Stanley lifted their target price on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. Finally, Piper Sandler raised their price objective on shares of Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.